| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Georg Golor, Ke Hu, Matthieu Ruffin, Alexandra Buchelt, Emmanuel Bouillaud, Yanfeng Wang, Mario Maldonad. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug design, development and therapy. vol 6. 2012-08-27. PMID:22573933. |
pasireotide (som230) is a multireceptor-targeted somatostatin analog with high binding affinity for four of the five somatostatin receptor subtypes (sst(1,2,3) and sst(5)), and potential clinical activity in several neuroendocrine and oncologic conditions, including acromegaly, cushing's disease, and neuroendocrine tumors (net). |
2012-08-27 |
2023-08-12 |
human |
| Stine Lyngvi Fougner, Olivera Casar-Borota, Ansgar Heck, Jens Petter Berg, Jens Bollersle. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clinical endocrinology. vol 76. issue 1. 2012-08-13. PMID:21722151. |
adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. |
2012-08-13 |
2023-08-12 |
Not clear |
| Yves Horsmans, Ke Hu, Matthieu Ruffin, Ying Wang, Dongweon Song, Emmanuel Bouillaud, Yanfeng Wang, Dago Mazur, Frans-Peter Botha, Douglas M Heuma. Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study. Journal of clinical pharmacology. vol 52. issue 4. 2012-07-27. PMID:22282526. |
pasireotide is a novel, multireceptor-targeted somatostatin analogue with high affinity for sst(1,2,3) and sst(5) under clinical evaluation in tumors of neuroendocrine origin, including cushing's disease, acromegaly, and neuroendocrine tumors. |
2012-07-27 |
2023-08-12 |
human |
| M Scacchi, C Carzaniga, G Vitale, L M Fatti, F Pecori Giraldi, M Andrioli, A Cattaneo, F Cavagnin. Assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor I. Journal of endocrinological investigation. vol 34. issue 9. 2012-07-16. PMID:21697649. |
assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor i. |
2012-07-16 |
2023-08-12 |
Not clear |
| Annamaria Cola. Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary. vol 15. issue 1. 2012-07-16. PMID:21713528. |
selected patients with acromegaly should consider first-line therapy or pre-treatment with somatostatin analogues prior to surgery to achieve biochemical control and improve cardiac dysfunction. |
2012-07-16 |
2023-08-12 |
Not clear |
| Michael Madsen, Thomas Krusenstjerna-Hafstrøm, Louise Møller, Britt Christensen, Mikkel Holm Vendelbo, Steen B Pedersen, Jan Frystyk, Niels Jessen, Troels Krarup Hansen, Hans Stødkilde-Jørgensen, Allan Flyvbjerg, Jens Otto L Jørgense. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial. The Journal of clinical endocrinology and metabolism. vol 97. issue 4. 2012-06-11. PMID:22298804. |
fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a gh receptor antagonist: a randomized clinical trial. |
2012-06-11 |
2023-08-12 |
Not clear |
| Mark R Postma, Romana T Netea-Maier, Gerrit van den Berg, Jens Homan, Wim J Sluiter, Margreet A Wagenmakers, Alfons C M van den Bergh, Bruce H R Wolffenbuttel, Ad R M M Hermus, André P van Bee. Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. European journal of endocrinology. vol 166. issue 4. 2012-05-24. PMID:22250074. |
quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. |
2012-05-24 |
2023-08-12 |
Not clear |
| Mark R Postma, Romana T Netea-Maier, Gerrit van den Berg, Jens Homan, Wim J Sluiter, Margreet A Wagenmakers, Alfons C M van den Bergh, Bruce H R Wolffenbuttel, Ad R M M Hermus, André P van Bee. Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. European journal of endocrinology. vol 166. issue 4. 2012-05-24. PMID:22250074. |
to assess the influence of long-acting somatostatin analogs (ssta) after initial pituitary surgery on long-term health-related quality of life (hr-qol) in relation to disease control in patients with acromegaly. |
2012-05-24 |
2023-08-12 |
Not clear |
| Chiu-Ming Ng, Chi-Chung Shek, Cheung-Hei Choi, Sau-Cheung Ti. Is withdrawal of somatostatin analogue therapy in patients with acromegaly associated with an increased risk of acute biliary problems? Clinical endocrinology. vol 68. issue 1. 2012-04-24. PMID:17803703. |
is withdrawal of somatostatin analogue therapy in patients with acromegaly associated with an increased risk of acute biliary problems? |
2012-04-24 |
2023-08-12 |
Not clear |
| Agata Bałdys-Waligórska, Anna Krzentowska-Korek, Filip Gołkowski, Grzegorz Sokołowski, Alicja Hubalewska-Dydejczy. The predictive value of the IGF-1 level in acromegaly patients treated by surgery and a somatostatin analogue. Endokrynologia Polska. vol 62. issue 5. 2012-04-03. PMID:22069100. |
the predictive value of the igf-1 level in acromegaly patients treated by surgery and a somatostatin analogue. |
2012-04-03 |
2023-08-12 |
Not clear |
| William H Ludlam, Lowell Anthon. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Advances in therapy. vol 28. issue 10. 2012-03-02. PMID:21964965. |
safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. |
2012-03-02 |
2023-08-12 |
Not clear |
| William H Ludlam, Lowell Anthon. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Advances in therapy. vol 28. issue 10. 2012-03-02. PMID:21964965. |
patients with either acromegaly or neuroendocrine tumors (net) can be treated with somatostatin analogs to relieve symptoms and improve disease control. |
2012-03-02 |
2023-08-12 |
Not clear |
| William H Ludlam, Lowell Anthon. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Advances in therapy. vol 28. issue 10. 2012-03-02. PMID:21964965. |
to fully explore and communicate any potential risks, we conducted a literature review and present a summary of the studies documenting the safety and tolerability of dose optimization with somatostatin analogs in patients with acromegaly and net. |
2012-03-02 |
2023-08-12 |
Not clear |
| Claudia Ramírez, Guadalupe Vargas, Baldomero González, Ashley Grossman, Julia Rábago, Ernesto Sosa, Ana Laura Espinosa-de-Los-Monteros, Moisés Mercad. Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying? European journal of endocrinology. vol 166. issue 1. 2012-02-01. PMID:21993154. |
somatostatin analogs (sa) have been used for over 25 years in the treatment of acromegaly. |
2012-02-01 |
2023-08-12 |
Not clear |
| Atsushi Ogo, Yuka Matoba, Yayoi Matsuda, Shinsuke Hiramats. A decrease in the dose of pegvisomant was needed for the treatment of acromegaly after adrenalectomy in a patient with coexisting preclinical Cushing's syndrome. Internal medicine (Tokyo, Japan). vol 50. issue 18. 2012-01-31. PMID:21921382. |
the patient was started on bromocriptine and then somatostatin analogues after the surgery; however, since her serum insulin-like growth factor-1 (igf-1) values remained above the age-adjusted normal range, the treatment for acromegaly was switched from somatostatin analogues to pegvisomant (10 mg daily), before a left laparoscopic adrenalectomy. |
2012-01-31 |
2023-08-12 |
Not clear |
| A Soto Moreno, R Guerrero Vázquez, E Venegas Moreno, S Palma Milla, J P Castaño, A Leal Cerr. Self-limited acute hepatotoxicity caused by pegvisomant. Pituitary. vol 14. issue 4. 2012-01-26. PMID:19266286. |
we present a case of acute severe hepatitis in a patient with acromegaly receiving combination therapy with somatostatin analogs and pegvisomant. |
2012-01-26 |
2023-08-12 |
Not clear |
| Sebastian J C M M Neggers, Wouter W de Herder, Richard A Feelders, A J van der Lel. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary. vol 14. issue 3. 2012-01-26. PMID:21221818. |
conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. |
2012-01-26 |
2023-08-12 |
Not clear |
| Sebastian J C M M Neggers, Wouter W de Herder, Richard A Feelders, A J van der Lel. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary. vol 14. issue 3. 2012-01-26. PMID:21221818. |
the efficacy of combined treatment in active acromegaly with both long-acting somatostatin analogs (srif) and pegvisomant (peg-v) has been well established. |
2012-01-26 |
2023-08-12 |
Not clear |
| P Caro. Acromegaly and pregnancy. Annales d'endocrinologie. vol 72. issue 4. 2012-01-03. PMID:21820101. |
in women with acromegaly due to growth hormone (gh)-secreting pituitary adenomas, the occurrence of pregnancy warrants consideration of: (1) the consequences of pregnancy on the pituitary adenoma including the tumor syndrome and gh/igf-1 secretion, (2) the consequence of gh/igf-1 hypersecretion on the pregnant woman and the fetus, (3) the consequences of pituitary surgery and medical treatment (dopamine agonists, somatostatin analogs, gh receptor antagonist) on the pregnant woman and the developing fetus. |
2012-01-03 |
2023-08-12 |
Not clear |
| Muhammad Wasif Sai. Rheumatoid arthritis associated with the use of Sandostatin® LAR® depot in a patient with pancreatic neuroendocrine tumor. An association or a coincidence? The first case report. JOP : Journal of the pancreas. vol 12. issue 4. 2011-12-15. PMID:21737909. |
sandostatin® lar® depot is a synthetic analogue of the naturally occurring hormone somatostatin and is indicated for certain patients with acromegaly and severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and for the long-term treatment of the profuse watery diarrhea associated with vip-secreting tumors in patients in whom initial treatment with immediate release sandostatin® injection has been shown to be effective and tolerated. |
2011-12-15 |
2023-08-12 |
Not clear |